A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma [Published online Keio J Med, 64, 62-64, by J-STAGE]

[Published online The Keio Journal of Medicine64, 62-64, by J-STAGE]
<Title:> A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma
<Author(s):> Yosuke Kitamura, Hidehiko Yoshii, Koshiro Nishimoto, Yusuke Shinchi, Shigeki Tokonabe, Masaya Takao, Yuichiro Daido
<Corresponding author E-Mill:> k.nishimoto(at)keio.jp
<Abstract:> Tyrosine kinase inhibitors such as sorafenib and axitinib were developed to treat malignancies, including stage IV renal cell carcinoma. Recently, we experienced a patient with pancreatic side effects from both sorafenib and axitinib. We report this case and include a discussion of the literature.
<Keywords:> renal cell carcinoma, sorafenib, axitinib, pancreatitis, side effects
<URL:> https://www.jstage.jst.go.jp/article/kjm/64/4/64_2015-0001-CR/_article